ABC | Volume 114, Nº3, March 2020

Original Article Kurmus et al. Discordance of lipoproteins and CAD severity Arq Bras Cardiol. 2020; 114(3):469-475 1. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113(19):2363- 72. 2. Catapano AL, Graham I, De Backer G, WiklundO, ChapmanMJ , Drexel H, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999-3058. 3. Kastelein JJ, van der SteegWA, Holme I, GaffneyM, Cater NB, Barter P, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation. 2008;117(23):3002-9. 4. Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med. 2001;161(11):1413-9. 5. Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, et al. A meta-analysis of low-density lipoprotein cholesterol, non- high-density lipoproteincholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011;4(3):337-45. 6. Verbeek R, Hovingh GK, Boekholdt SM. Non-high-density lipoprotein cholesterol: current status as cardiovascular marker. Curr Opin Lipidol. 2015;26(6):502-10. 7. Mora S, Buring JE, Ridker PM. Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation. 2014;129(5):553-61. 8. Zhang Y , WuNQ, Li S, Zhu CG, Guo YL, Qing P , et al. Non-HDL-C is a better predictor for the severity of coronary atherosclerosis comparedwith LDL-C. Heart Lung Circ. 2016;25(10):975-81. 9. Gensini GG. Amoremeaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51(3):606. 10. Serruys PW,MoriceMC, KappeteinAP, ColomboA, Holmes DR,MackMJ, et al. Percutanous coronary intervention versus coronary artery bypass grafting for severe coronary artery disease. N Eng J Med. 2009;360(10):961-72. 11. Chen ZW , Chen YH, Qian JY , Ma JY, Ge JB. Validation of a novel clinical prediction score for severe coronary artery diseases before elective coronary angiography. PLoS One. 2014;9(4):e94493. 12. Pischon T , Girman CJ , Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high- density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 2005;112(22):3375-83. 13. WongcharoenW , Sutthiwutthichai S, Gunaparn S, Phrommintikul A. Is non- HDL-cholesterol a better predictor of long-term outcome in patients after acutemyocardial infarction compared to LDL-cholesterol? : a retrospective study. BMC Cardiovasc Disord. 2017;17(1):10. 14. Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307(12):1302-9. 15. Varbo A, Benn M, Tybjærg-Hansen A, Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61(4):427-36. 16. Bittencourt MS, Santos RD, Staniak H, Sharovsky R, Kondapally R, Vallejo- Vaz AJ, et al. Relation of fasting triglyceride rich lipoprotein cholesterol to coronary artery calcium score (from the ELSA-Brasil Study). Am J Cardiol. 2017;119(9):1352-58. 17. Sniderman A, McQueen M, Contois J, Williams K, Furberg CD. Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol? J Clin Lipidol. 2010;4(3):152-5. 18. Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC Jr. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol. 2011;5(2):105-13. 19. Cromwell WC, Otvos JD, Keyes MJ, Pencina MJ, Sullivan L, Vasan RS, et al. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study - Implications for LDL management. J Clin Lipidol. 2007;1(6):583-92. 20. SnidermanAD, St-PierreAC, CantinB , DagenaisGR , Després JP , LamarcheB . Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexesofatheroscleroticrisk.AmJCardiol.2003;91(10):1173-7. 21. Sniderman AD, Islam S, Yusuf S, McQueen MJ. Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study. Atherosclerosis. 2012;225(2):444-9. 22. Sniderman AD , IslamS, Yusuf S, McQueenMJ. Is the superiority of apoB over non-HDL-C as amarker of cardiovascular risk in the INTERHEART study due to confounding by related variables? J Clin Lipidol. 2013;7(6):626-31. 23. Sniderman AD, Lamarche B, Contois JH, de Graaf J. Discordance analysis and the Gordian Knot of LDL and non-HDL cholesterol versus apoB. Curr Opin Lipidol. 2014;25(6):461-7. 24. Elshazly MB, Martin SS, Blaha MJ, Joshi PH, Toth PP , McEvoy JW , et al. Non-high-density lipoprotein cholesterol, guideline targets, and population percentiles for secondary prevention in 1.3 million adults: the VLDL-2 study (very large database of lipids). J Am Coll Cardiol. 2013;62(21):1960-5. 25. AbateN , VegaGL, Grundy SM. Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100. Atherosclerosis. 1993;104(1-2):159-71. 26. Kuwabara K, Harada S, Sugiyama D, Kurihara A, Kubota Y, Higashiyama A, et al. Relationship between non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol in the general population. J Atheroscler Thromb. 2016;23(4):477-90. 27. Budde T , Fechtrup C, Bösenberg E, Vielhauer C, Enbergs A, Schulte H, et al. Plasma Lp(a) levels correlate with number, severity, and length-extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis. Arterioscler Thromb. 1994;14(11):1730-6. 28. Kral BG, Kalyani RR, Yanek LR, Vaidya D, Fishman EK, Becker DM, et al. Relation of plasma lipoprotein(a) to subclinical coronary plaque volumes, three-vessel and left main coronary disease, and severe coronary stenoses in apparently healthy African-Americans with a family history of early-onset coronary artery Disease. Am J Cardiol. 2016;118(5):656-61. References Study Association This study is not associated with any thesis or dissertation work. Ethics approval and consent to participate This article does not contain any studies with human participants or animals performed by any of the authors. 474